Alveolus Bio
Alveolus Bio is a preclinical-stage biotech developing first-in-class inhaled live biotherapeutics via its proprietary resMIT® platform to treat chronic respiratory diseases including IPF, COPD, and NCFBE, targeting patient populations in the US with future monetization through licensing and pharma partnerships.
- Company typePrivate
- Founded2020
- HeadquartersBirmingham, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Alveolus Bio does
Alveolus Bio Inc. is a preclinical-stage biopharmaceutical company developing first-in-class inhaled live biotherapeutics (LBPs) for chronic respiratory diseases. The company was spun out of ResBiotic Inc in October 2021 and is headquartered in Birmingham, Alabama, with a secondary office in Cambridge, Massachusetts. It operates with 1-10 employees as a privately held venture-backed corporation.
The company's core technology is the proprietary resMIT® platform, which delivers safe, targeted commensal bacteria directly to the lungs to address two mechanistic targets: fibroblast dysfunction in Idiopathic Pulmonary Fibrosis (IPF) and neutrophilic inflammation in chronic obstructive pulmonary disease (COPD), Non-Cystic Fibrosis Bronchiectasis (NCFBE), and other respiratory indications. The platform originates from over a decade of pulmonary microbiome research conducted by founders Dr. C Vivek Lal (CSO) and Dr. Amit Gaggar (CMO) at the University of Alabama at Birmingham. The preclinical pipeline currently comprises three named programs — IPF (orphan designation), COPD (~15M US patients), and NCFBE (rare disease) — with broader indication expansion signaled through the Shilpa Medicare partnership to include Bronchopulmonary Dysplasia and pulmonary fibrosis.
Alveolus Bio has no commercial revenue and no products on market. Its operating model is grant- and equity-funded preclinical development, with capital sourced from a $4.5M seed round at spin-out (October 2021), a $2.5M NIH SBIR FastTrack grant from NHLBI (February 2023), and a $2.0M strategic financing from Shilpa Medicare (July 2025). The company presents at biotech investor conferences (Biotech Showcase, BIO CEO & Investor Conference) to engage institutional investors and pharmaceutical partners, and pursues clinical development partnerships as its primary go-to-market motion. Future monetization is expected through licensing or partnership transactions rather than direct commercialization, consistent with the preclinical stage and orphan/rare disease focus.
Alveolus Bio firmographics
Firmographics- Name
- Alveolus Bio
- Legal name
- Alveolus Bio Inc.
- Website
- https://www.alveolusbio.com/
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Alveolus Bio is a preclinical-stage biotech developing first-in-class inhaled live biotherapeutics via its proprietary resMIT® platform to treat chronic respiratory diseases including IPF, COPD, and NCFBE, targeting patient populations in the US with future monetization through licensing and pharma partnerships.
- Ownership category
- akta.pro rank
Alveolus Bio industry classification
Industry- Product category
- Inhaled Pulmonary Biotherapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Live Biotherapeutic Products (LBPs) (HLAAAFAA)
- akta.pro secondary industries
- Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ)
Keywords
Where Alveolus Bio is headquartered
LocationHeadquarters
- HQ city
- Birmingham
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Alveolus Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Government Research Funding: NIH SBIR FastTrack grants to fund early-stage research and development for inhaled biotherapeutics targeting respiratory diseases.
- Strategic Investment: Strategic financing from pharmaceutical partners to advance clinical trials for pulmonary therapeutics platform.
- Pharmaceutical Development: Pre-commercial stage biotech company developing therapeutics for respiratory illnesses; revenue model not yet established as company is in preclinical development phase.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Alveolus Bio product offering
Product offeringCore offering
Alveolus Bio develops first-in-class inhaled live biotherapeutic products (LBPs) for chronic respiratory diseases using its proprietary resMIT platform, which delivers safe, targeted bacteria directly to lung tissue. The company's preclinical pipeline addresses fibroblast dysfunction in Idiopathic Pulmonary Fibrosis (IPF) and neutrophilic inflammation in Chronic Obstructive Pulmonary Disease (COPD) and Non-Cystic Fibrosis Bronchiectasis (NCFBE), targeting indications where the current standard of care lacks targeted biotherapeutic approaches.
Product overview
Alveolus Bio is a biopharmaceutical company pioneering first-in-class inhaled biotherapeutics for chronic lung diseases. The company's core offering is the proprietary resMIT® platform, which delivers safe, targeted bacteria directly to the lungs to address fibroblast dysfunction and neutrophilic inflammation. The product portfolio includes three preclinical programs targeting Idiopathic Pulmonary Fibrosis (IPF), Chronic Obstructive Pulmonary Disease (COPD), and Non-Cystic Fibrosis Bronchiectasis (NCFBE). The resMIT platform serves as the foundational technology enabling these live biotherapeutic products for respiratory disease treatment.
Differentiator
Problem solved
Functional benefit
Products and services
- resMIT® Platform Proprietary technology platform for delivering safe, targeted commensal bacteria and their byproducts directly to the lungs via inhalation to address fibroblast dysfunction and neutrophilic inflammation. Developed to enable inhaled live biotherapeutic products for chronic respiratory diseases.
- IPF (Idiopathic Pulmonary Fibrosis) Program Preclinical inhaled live biotherapeutic product leveraging the resMIT platform to target fibroblast dysfunction in Idiopathic Pulmonary Fibrosis (IPF), designated as an orphan disease. Aimed at patients with progressive lung scarring caused by fibroblast dysfunction.
- COPD Program Preclinical inhaled live biotherapeutic product leveraging the resMIT platform to target neutrophilic inflammation in Chronic Obstructive Pulmonary Disease (COPD), addressing approximately 15 million patients in the US. Supported by a $2.5M NIH SBIR FastTrack grant for Phase I and II research over three years.
- NCFBE (Non-Cystic Fibrosis Bronchiectasis) Program Preclinical inhaled live biotherapeutic product leveraging the resMIT platform to target neutrophilic inflammation in Non-Cystic Fibrosis Bronchiectasis (NCFBE), a rare disease indication characterized by chronic respiratory inflammation and lung damage.
Quantifiable outcome
- Phase I and II research supported over three years for COPD treatment
Companies that use Alveolus Bio
Customer profileSegments6 records
Ideal customer profiles2 records
Alveolus Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Alveolus Bio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- University of Alabama at Birmingham (UAB)coreAlveolus Bio originated from Dr. Vivek Lal's Pulmonary Microbiome Lab and Dr. Amit Gaggar's Program in Lung Protease and Matrix Biology at UAB. The company maintains collaborations with UAB researchers for preclinical drug development and clinical research infrastructure.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Alveolus Bio competitors and assessment
Company assessmentDirect peers
- Vedanta Biosciences: Vedanta Biosciences is a clinical-stage microbiome therapeutics company developing defined bacterial consortia as live biotherapeutic products for immune-mediated diseases. Both companies are building LBP platforms targeting inflammation, though Vedanta focuses on oral delivery and gastrointestinal indications rather than inhaled respiratory delivery.
- Seres Therapeutics: Seres Therapeutics is a pioneer in microbiome therapeutics, with an approved oral live biotherapeutic (VOWST for recurrent C. difficile) and a pipeline in inflammatory diseases. Comparable to Alveolus Bio as a fellow LBP developer, though Seres uses oral delivery while Alveolus Bio's resMIT is inhaled.
- 4D pharma: 4D pharma was a clinical-stage microbiome therapeutics company developing live biotherapeutics across oncology, respiratory, and CNS indications, including a Phase II program in asthma. Comparable as a direct LBP peer targeting respiratory disease.
- ResBiotic: ResBiotic is the parent company that spun out Alveolus Bio and continues to sell consumer lung health probiotic products (resB Lung Support) while Alveolus Bio pursues the pharmaceutical development. Closely related via shared founders and pulmonary microbiome focus.
- BiomX: BiomX is a clinical-stage microbiome company developing phage-based and bacterial therapeutics, with programs in chronic respiratory disease (e.g., nontuberculous mycobacteria lung disease). Comparable as a fellow microbiome company targeting pulmonary indications.
Emerging players
- Second Genome: Second Genome is a clinical-stage microbiome drug discovery company developing therapeutics that modulate the microbiome for inflammatory and metabolic diseases. Comparable as a fellow emerging LBP/biotherapeutic developer, though focused on non-pulmonary indications.
- Galapagos NV: Galapagos developed ziritaxestat and other IPF candidates and maintains an active respiratory R&D pipeline. Comparable as a biopharma developing novel therapeutics for IPF and related fibrotic lung diseases.
Broad incumbents
- Boehringer Ingelheim: Boehringer Ingelheim markets OFEV (nintedanib) for IPF and a broad respiratory portfolio including Spiriva for COPD. Comparable as the dominant large-pharma incumbent in Alveolus Bio's two lead indications (IPF and COPD), against which any approved therapy will compete.
- FibroGen: FibroGen developed and commercializes pamrevlumab (with AstraZeneca) and has historically been active in IPF drug development. Comparable as an established pulmonary fibrosis therapeutics developer competing in Alveolus Bio's IPF indication.
- AstraZeneca: AstraZeneca markets a leading COPD franchise including Breztri Aerosphere, Symbicort, and Fasenra, and is partnered with FibroGen on IPF development. Comparable as the dominant respiratory biopharma against which any novel COPD or IPF therapy must compete.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Alveolus Bio social profiles
Digital presenceAlveolus Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alveolus Bio leadership team
Management profileNumber of profiles
Profiles6 records
Alveolus Bio funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alveolus Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alveolus Bio
What does Alveolus Bio do?
Alveolus Bio develops first-in-class inhaled live biotherapeutic products (LBPs) for chronic respiratory diseases using its proprietary resMIT platform, which delivers safe, targeted bacteria directly to lung tissue. The company's preclinical pipeline addresses fibroblast dysfunction in Idiopathic Pulmonary Fibrosis (IPF) and neutrophilic inflammation in Chronic Obstructive Pulmonary Disease (COPD) and Non-Cystic Fibrosis Bronchiectasis (NCFBE), targeting indications where the current standard of care lacks targeted biotherapeutic approaches.
Is Alveolus Bio a public or private company?
Alveolus Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Alveolus Bio founded?
Alveolus Bio was founded in 2020. It employs 1 to 10 people.
Where is Alveolus Bio based?
Alveolus Bio is headquartered in Birmingham, United States, in the North America region.
How does Alveolus Bio make money?
Three revenue lines are on record. Government Research Funding is the primary driver. The others are strategic Investment and pharmaceutical Development.
Who are Alveolus Bio's main competitors?
Direct peers on record are Vedanta Biosciences, Seres Therapeutics, 4D pharma, ResBiotic and BiomX. Emerging players are Second Genome and Galapagos NV. Broad incumbents are Boehringer Ingelheim, FibroGen and AstraZeneca.
Does Alveolus Bio have an API?
No public API is recorded for Alveolus Bio.
What industry is Alveolus Bio in?
Alveolus Bio's product category is Inhaled Pulmonary Biotherapeutics. Its primary akta.pro industry code is HLAAAFAA, Live Biotherapeutic Products (LBPs), with a secondary code of HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.